FGFR2 and neoplasm: More recently, the FGFR2-targeting antibody BAY 1,179,470 has also been developed as a targeted alpha-particle therapy (TAT), which utilizes a monoclonal antibody to deliver an alpha-particle-emitting payload to tumour cells.